The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: A randomised study

Gut

Volumn 60, Issue 8, 2011, Pages 1068-1075

  Vermeire, Séverine ^a   Ghosh, Subrata ^b   Panes, Julian ^c   Dahlerup, Jens F ^d   Luegering, Andreas ^e   Sirotiakova, Jana ^f   Strauch, Ulrike ^g   Burgess, Gary ^h   Spanton, Jacqueline ^h   Martin, Steven W ^h   Niezychowski, Wojciech ^h  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF CALGARY   (Canada)

^c HOSPITAL CLÍNIC   (Spain)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f Internal Clinic Department of Clinical Pharmacology   (Slovakia)

^g UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^h PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4BETA7 INTEGRIN; AZATHIOPRINE; BECLOMETASONE; BETAMETHASONE; CALGRANULIN; CORTISONE ACETATE; HYDROCORTISONE; INFLIXIMAB; INTEGRIN; MERCAPTOPURINE; MESALAZINE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE ANTIBODY; OLSALAZINE; PF 00547659; PLACEBO; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BACKACHE; COLONOSCOPY; CONTROLLED STUDY; DISEASE ACTIVITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ECZEMA; ENTERITIS; ERYTHEMA; FATIGUE; FEMALE; FLU LIKE SYNDROME; GASTROENTERITIS; HOT FLUSH; HUMAN; HUMAN CELL; IMMUNOGENICITY; INFLUENZA; INSOMNIA; IRON DEFICIENCY ANEMIA; LOW DRUG DOSE; LOWER ABDOMINAL PAIN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; PERIPHERAL EDEMA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SINGLE DRUG DOSE; TREATMENT RESPONSE; ULCERATIVE COLITIS; UPPER ABDOMINAL PAIN; VOMITING;

ANTIBODIES, MONOCLONAL; CELL ADHESION; COLITIS, ULCERATIVE; COLONOSCOPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULINS; INFUSIONS, INTRAVENOUS; LYMPHOCYTES; MALE; MIDDLE AGED; MUCOPROTEINS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79960336916     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.226548     Document Type: Article

References (38)

1. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76. (Pubitemid 41770166)
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9. (Pubitemid 34621118)
3. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50. (Pubitemid 47080388)
4. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65. (Pubitemid 46108762)
5. Caviglia R, Boskoski I, Cicala M. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opin Drug Saf 2008;7:617-32.
6. Lin J, Ziring D, Desai S, et al. TNFα blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008;126:13-30. (Pubitemid 350266448)
7. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha-4 integrin in active Crohn's disease. Gastroenterology 2001;121:268-74. (Pubitemid 32729374)
8. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32. (Pubitemid 36026343)
9. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912-25. (Pubitemid 41565956)
10. Gordon FH, Hamilton MI, Donoghue S, et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002;16:699-705. (Pubitemid 34407517)
11. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-81. (Pubitemid 41132342)
12. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-74. (Pubitemid 41132341)
13. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-8. (Pubitemid 41132340)
14. Major EO, Amemiya K, Tornatore CS, et al. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 1992;5:49-73.
15. Stüve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006;59:743-7. (Pubitemid 43673151)
16. Stüve O. The effects of natalizumab on the innate and adaptive immune system in the central nervous system. J Neurol Sci 2008;274:39-41.
17. Niino M, Bodner C, Simard ML, et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006;59:748-54. (Pubitemid 43673152)
18. Li YY, Perez HD, Zollner TM. Fatalities in natalizumab treatment - a 'no go' for leukocyte recirculation approaches? Expert Opin Ther Targets 2006;10:489-99.
19. Guagnozzi D, Caprilli R. Natalizumab in the treatment of Crohn's disease. Biologics 2008;2:275-84.
20. Hamann A, Andrew DP, Jablonski-Westrich D, et al. Role of alpha 4-integrins in lymphocyte homing to mucosal tissues in vivo. J Immunol 1994;152:3282-93.
21. Berlin C, Berg EL, Briskin MJ, et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993;74:185-95.
22. Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997;151:97-110. (Pubitemid 27283962)
23. Picarella D, Hurlbut P, Rottman J, et al. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of SCID mice reconstituted with CD45RBhigh CD4+ T cells. J Immunol 1997;158:2099-106. (Pubitemid 127469991)
24. Hokari R, Kato S, Matsuzaki K, et al. Involvement of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in the pathogenesis of granulomatous colitis in rats. Clin Exp Immunol 2001;126:259-65. (Pubitemid 32995140)
25. Farkas S, Hornung M, Sattler C, et al. Blocking MAdCAM-1 in vivo reduces leukocyte extravasation and reverses chronic inflammation in experimental colitis. Int J Colorectal Dis 2006;21:71-8. (Pubitemid 41829768)
26. Kato S, Hokari R, Matsuzaki K, et al. Amelioration of murine experimental colitis by inhibition of mucosal addressin cell adhesion molecule-1. J Pharmacol Exp Ther 2000;295:183-9.
27. Shigematsu T, Specian RD, Wolf RE, et al. MAdCAM mediates lymphocyte-endothelial cell adhesion in a murine model of chronic colitis. Am J Physiol Gastrointest Liver Physiol 2001;281:G1309-15.
28. Teramoto K, Miura S, Tsuzuki Y, et al. Increased lymphocyte trafficking to colonic microvessels is dependent on MAdCAM-1 and CeC chemokine mLARC/CC20 in DSS-induced mice colitis. Clin Exp Immunol 2005;139:421-8. (Pubitemid 40333253)
29. Goto A, Arimura Y, Shinomura Y, et al. Antisense therapy of MAdCAM-1 for trinitrobenzenesulfonic acid-induced murine colitis. Inflamm Bowel Dis 2006;12:758-65. (Pubitemid 44253761)
30. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin. N Engl J Med 2005;352:2499-507. (Pubitemid 41007865)
31. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the α4β7 integrin. Clin Gastroenterol Hepatol 2008;6:1370-7.
32. Allavena R, Noy S, Andrews M, et al. CNS elevation of vascular and not mucosal addressin cell adhesion molecules in patients with multiple sclerosis. Am J Pathol 2010;176:556-62.
33. Pullen N, Molloy E, Carter D, et al. Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody. Br J Pharmacol 2009;157:281-93.
34. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med 1987;317:1625-9. (Pubitemid 18010466)
35. Xiang JY, Ouyang Q, Li GD, et al. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol 2008;14:53-7. (Pubitemid 351314326)
36. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005;54:364-8. (Pubitemid 40299092)
37. Ho GT, Lee HM, Brydon G, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol 2009;104:673-8.
38. Martin SW, Magnusson MO, Matthews IT, et al. Mechanistic population pharmacokinetics (PK) model of PF-00547659, a fully human IgG2 anti-MAdCAM antibody, in ulcerative colitis patients: results of a first in human (FIH) study. Gastroenterology 2009;136(Suppl 1):Ae641.